Poster: AML-108 SELECT-AML-1 Trial in Progress: A Phase 2 Study of Tamibarotene in Combination With Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-Positive AML who are Ineligible for Standard Induction Therapy
Clinical Lymphoma Myeloma and Leukemia（2022）
摘要
U.S. and France.
更多查看译文
关键词
AML,acute myeloid leukemia,retinoic acid receptor (RAR),clinical trial,Trial-in-Progress
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要